Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Joseph A Mancini"'
Autor:
Charlotte Avet, Louis Gendron, Camil Elie Sayegh, Joseph A. Mancini, Florence Gross, Christian Le Gouill, Meriem Semache, Youssef L. Bennani, Claudio Sturino, Michel Bouvier, Sébastien Grastilleur
Publikováno v:
Communications Biology
Protease-activated receptor-2 (PAR2) is involved in inflammatory responses and pain, therefore representing a promising therapeutic target for the treatment of immune-mediated inflammatory diseases. However, as for other GPCRs, PAR2 can activate mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe33a82e299b5c3d3b01de44cc4447ab
https://doi.org/10.1038/s42003-020-01453-8
https://doi.org/10.1038/s42003-020-01453-8
Autor:
Mark J. Eisenberg, Sarah B. Windle, Joseph G. Mancini, Lauren Adye-White, Louise Pilote, Genevieve Gore, Bettina Habib, Lawrence Joseph, Roland Grad, Kristian B. Filion
Publikováno v:
American Journal of Preventive Medicine. 51:1060-1071
Context Treatment guidelines recommend the use of combination therapies for smoking cessation, particularly behavioral therapy (BT) as an adjunct to pharmacotherapy. However, these guidelines rely on previous reviews with important limitations. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f95a4d8a138ad01b673600e6ccc85f78
https://doi.org/10.1016/j.amepre.2016.07.011
https://doi.org/10.1016/j.amepre.2016.07.011
Publikováno v:
The American Journal of Cardiology. 118:23-31
American College of Cardiology Foundation/American Heart Association guidelines no longer recommend the use of routine aspiration thrombectomy during primary percutaneous coronary intervention (PCI). This is based on evidence from recent randomized c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e13613bb7e5848939c2b897094ea7450
https://doi.org/10.1016/j.amjcard.2016.04.008
https://doi.org/10.1016/j.amjcard.2016.04.008
Autor:
Youssef L. Bennani, Joseph A. Mancini, Christian Le Gouill, Meriem Semache, Florence Gross, Camil Elie Sayegh, Charlotte Avet, Michel Bouvier
Publikováno v:
The FASEB Journal. 32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdc2850dae98f4abaa6244caa5404848
https://doi.org/10.1096/fasebj.2018.32.1_supplement.555.13
https://doi.org/10.1096/fasebj.2018.32.1_supplement.555.13
Autor:
Lawrence Joseph, Joseph G. Mancini, Salvatore Mottillo, Mark J. Eisenberg, Kristian B. Filion, Vincenzo Forgetta, Maria Eberg
Publikováno v:
The American journal of cardiology. 119(2)
The American College of Cardiology Foundation /American Heart Association guidelines recommend a weight-based dose of unfractionated heparin (UFH) for primary percutaneous coronary intervention (PCI). However, it is convention to administer a fixed-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9653a2ac1e022443117de2bc852fa22b
https://pubmed.ncbi.nlm.nih.gov/27814785
https://pubmed.ncbi.nlm.nih.gov/27814785
Autor:
Sarah B, Windle, Kristian B, Filion, Joseph G, Mancini, Lauren, Adye-White, Lawrence, Joseph, Genevieve C, Gore, Bettina, Habib, Roland, Grad, Louise, Pilote, Mark J, Eisenberg
Publikováno v:
American journal of preventive medicine. 51(6)
Treatment guidelines recommend the use of combination therapies for smoking cessation, particularly behavioral therapy (BT) as an adjunct to pharmacotherapy. However, these guidelines rely on previous reviews with important limitations. This study's
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a81fb1d81d96a092c48716b7bec44f0c
https://pubmed.ncbi.nlm.nih.gov/27617367
https://pubmed.ncbi.nlm.nih.gov/27617367
Autor:
Jianfeng, Xu, Hidetaka, Morinaga, Dayoung, Oh, Pingping, Li, Ai, Chen, Saswata, Talukdar, Yaël, Mamane, Joseph A, Mancini, Andrea R, Nawrocki, Eduardo, Lazarowski, Jerrold M, Olefsky, Jane J, Kim
Publikováno v:
The Journal of Immunology. 189:1992-1999
GPR105, a G protein-coupled receptor for UDP-glucose, is highly expressed in several human tissues and participates in the innate immune response. Because inflammation has been implicated as a key initial trigger for type 2 diabetes, we hypothesized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866430edd12b15c921d58250fc1b0a12
https://doi.org/10.4049/jimmunol.1103207
https://doi.org/10.4049/jimmunol.1103207
Autor:
Kathryn Skorey, Christine Brideau, Martine Hamel, Nicolas Morin, Stacia Kargman, Martin Henault, Joseph A. Mancini, Alex G. Therien, Christopher I. Bayly, Huda Hyjazie
Publikováno v:
SLAS Discovery. 16:1098-1105
P2Y14 is a member of the pyrimidinergic GPCR family. UDP-Glc has been previously shown to activate human P2Y14, whereas UDP was unable to activate the receptor. In this study, the authors used conventional and nonconventional methods to further chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90c362a0cde6537b174fa205a0606a9
https://doi.org/10.1177/1087057111415525
https://doi.org/10.1177/1087057111415525
Autor:
Joel Robichaud, Nicolas Morin, Sébastien Gagné, Michel Belley, Lianhai Li, Genevieve Lavallee, Geoffrey K. Tranmer, Yves Gareau, Erin F. Mulrooney, W. Cameron Black, Stacia Kargman, Jean-François Lévesque, Joseph A. Mancini, Jacques Yves Gauthier, Jean-François Fournier, Denis Deschenes, Jin Wu, Martine Hamel, Zhaoyin Wang, Michel Therien, Martin Henault, Yaël Mamane, Huda Hyjazie
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:2836-2839
A weak, UDP-competitive antagonist of the pyrimidinergic receptor P2RY(14) with a naphthoic acid core was identified through high-throughput screening. Optimization provided compounds with improved potency but poor pharmacokinetics. Acylglucuronidati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e882d0ef4cdd630e17158a34b627a7e
https://doi.org/10.1016/j.bmcl.2011.03.081
https://doi.org/10.1016/j.bmcl.2011.03.081
Autor:
Robert Gordon, Lijing Xu, Michel Therien, W. Cameron Black, Martin Henault, Yaël Mamane, Chi-Chung Chan, Vouy Linh Truong, Michel Belley, Huda Hyjazie, Daniel Guay, Geoffrey K. Tranmer, Jeancarlo DeLuca, Zhaoyin Wang, Stacia Kargman, Christian Beaulieu, Martine Hamel, Sheldon Crane, Joseph A. Mancini, Lianhai Li, Nicolas Morin, Yves Gareau
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:2832-2835
A weak antagonist of the pyrimidinergic receptor P2Y(14) containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f402223a76e1d1b4bfb68e56fd6b8f8f
https://doi.org/10.1016/j.bmcl.2011.03.084
https://doi.org/10.1016/j.bmcl.2011.03.084